- It is necessary to monitor the body weight, body mass index (BMI), waist circumference, and lipid profile in patients taking orlistat.

- The levels of cyclosporine, antiepileptic, and HIV viral load require monitoring when using orlistat in conjunction with these medications.

- Patients with diabetes might need to adjust the dose of diabetes medicine, as weight loss can affect glycemic control.

- Monitor the impact of Weight loss on Quality of Life-Lite (IWQOL-Lite), a widely used tool in assessingÂ weight-loss interventions in clinical trials.

- According to the (AACE/ACE) American Association of Clinical Endocrinologists, Medical Guidelines & American College of Endocrinology guidelines, patients receiving orlistat should be monitored for cholelithiasis in patients with mild hepatic impairment. In patients receiving orlistat, there is a risk of nephrolithiasis; monitor for flank pain and hematuria.